| Gastro-enteropancreatic neuroendocrine tumor
Afinitor vs Somatuline Depot
Side-by-side clinical, coverage, and cost comparison for gastro-enteropancreatic neuroendocrine tumor.Deep comparison between: Afinitor vs Somatuline Depot with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSomatuline Depot has a higher rate of injection site reactions vs Afinitor based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Somatuline Depot but not Afinitor, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Afinitor
Somatuline Depot
At A Glance
Oral
Daily
mTOR inhibitor
SC injection
Every 4 weeks
Somatostatin analog
Indications
- Hormone receptor positive breast cancer
- Neuroendocrine tumor of pancreas
- Gastro-enteropancreatic neuroendocrine tumor
- Renal Cell Carcinoma
- Angiomyolipoma of kidney
- Subependymal Giant Cell Astrocytoma
- Seizures, Focal
- Acromegaly
- Gastro-enteropancreatic neuroendocrine tumor
- Malignant Carcinoid Syndrome
Dosing
Hormone receptor positive breast cancer 10 mg orally once daily in combination with exemestane until disease progression or unacceptable toxicity.
Neuroendocrine tumor of pancreas, Gastro-enteropancreatic neuroendocrine tumor 10 mg orally once daily until disease progression or unacceptable toxicity.
Renal Cell Carcinoma 10 mg orally once daily until disease progression or unacceptable toxicity.
Angiomyolipoma of kidney 10 mg orally once daily until disease progression or unacceptable toxicity.
Subependymal Giant Cell Astrocytoma Starting dose 4.5 mg/m2 orally once daily (AFINITOR or AFINITOR DISPERZ); titrate to trough concentration 5-15 ng/mL.
Seizures, Focal Starting dose 5 mg/m2 orally once daily (AFINITOR DISPERZ); titrate to trough concentration 5-15 ng/mL.
Acromegaly 90 mg deep SC injection every 4 weeks for 3 months; adjust thereafter to 60-120 mg every 4 weeks based on GH and/or IGF-1 levels; controlled patients may extend to 120 mg every 6 or 8 weeks. Starting dose reduced to 60 mg every 4 weeks in moderate or severe renal or hepatic impairment.
Gastro-enteropancreatic neuroendocrine tumor, Malignant Carcinoid Syndrome 120 mg deep SC injection every 4 weeks; if already receiving treatment for GEP-NET, do not administer an additional dose for carcinoid syndrome.
Contraindications
- Clinically significant hypersensitivity to everolimus or other rapamycin derivatives
- History of hypersensitivity to lanreotide (including angioedema and anaphylaxis)
Adverse Reactions
Most common (>=30%) Stomatitis, infections, rash, fatigue, diarrhea, decreased appetite.
Serious Non-infectious pneumonitis, infections, severe hypersensitivity reactions, angioedema, stomatitis, renal failure, impaired wound healing, metabolic disorders (hyperglycemia, dyslipidemia), myelosuppression, radiation sensitization and recall.
Postmarketing Thrombotic microangiopathy, cardiac failure (including with pulmonary hypertension), acute pancreatitis, cholecystitis, cholelithiasis, sepsis, reflex sympathetic dystrophy, arterial thrombotic events, lymphedema, radiation sensitization and recall.
Most common (>5%) Diarrhea, abdominal pain, nausea, constipation, flatulence, vomiting, loose stools, cholelithiasis, injection site reactions, musculoskeletal pain, arthralgia, headache, hyperglycemia, hypertension, dizziness
Serious Cholelithiasis and complications of cholelithiasis, hyperglycemia and hypoglycemia, cardiovascular abnormalities, thyroid function abnormalities, steatorrhea and malabsorption of dietary fats
Postmarketing Pancreatic exocrine insufficiency, steatorrhea, cholecystitis, cholangitis, pancreatitis, angioedema, anaphylaxis, injection site abscess
Pharmacology
Everolimus is an mTOR inhibitor that binds the intracellular protein FKBP-12 to form an inhibitory complex with mTORC1, suppressing downstream effectors (S6K1, 4E-BP1) involved in protein synthesis, cell proliferation, and angiogenesis, and reducing HIF-1 and VEGF expression; mTOR pathway dysregulation occurs in several human cancers and in tuberous sclerosis complex.
Lanreotide is a synthetic octapeptide analog of natural somatostatin with high binding affinity for somatostatin receptors SSTR2 and SSTR5; it inhibits growth hormone and IGF-1 secretion, reduces carcinoid syndrome mediators (urinary 5-HIAA), and suppresses various endocrine, neuroendocrine, exocrine, and paracrine functions.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Afinitor
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (0/12)
Somatuline Depot
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Afinitor
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (6/8)
Somatuline Depot
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Afinitor
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Somatuline Depot
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Afinitor.
Cost estimate not availableAssistance Fund: Acromegaly: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AfinitorView full Afinitor profile
Somatuline DepotView full Somatuline Depot profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.